AAPL 189.07 +0.3 (+0.16%)MSFT 117.02 -0.72 (-0.62%)FB 167.35 +1.05 (+0.63%)ZNGA 5.3 -0.01 (-0.19%)NVDA 175.17 +1.31 (+0.75%)WBA 61.7 +0.14 (+0.23%)GOOG 1184.77 -8.35 (-0.70%)PIH 5.45 -0.16 (-2.85%)
AAPL 189.07 +0.3 (+0.16%)MSFT 117.02 -0.72 (-0.62%)FB 167.35 +1.05 (+0.63%)ZNGA 5.3 -0.01 (-0.19%)NVDA 175.17 +1.31 (+0.75%)WBA 61.7 +0.14 (+0.23%)GOOG 1184.77 -8.35 (-0.70%)PIH 5.45 -0.16 (-2.85%)

Balance Sheet ACHN Quote Achillion P

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
CashAndCashEqui 77 43 50
ShortTermInvest 287 257 221
Cash 364 300 271
AccountReceivab 15 1 0
Inventories 0 0 0
DeferredIncomeT 0 0 0
OtherCurrentAss 2 1 2
TotalCurrentAss 383 304 275
PPE 11 11 11
AccumulatedDepr -7 -8 -9
NetPPE 3 3 2
EquityAndOtherI 28 31 0
Goodwill 0 0 0
IntangibleAsset 0 0 0
OtherLTAssets 0 0 0
TotalNonCurrent 31 34 2
TotalAssets 414 338 278
ShortTermDebt 0 0 0
AccountsPayable 7 5 2
TaxesPayable 0 0 0
AccruedLiabilit 7 3 5
DeferredRevenue 0 0 0
OtherCurrentLia 0 4 4
TotalCurrentLia 14 13 12
Debt 0 0 0
DeferredTaxesLi 0 0 0
DeferredRevenue 0 0 0
OtherLTLiabilit 0 0 0
TotalNonCurrent 0 0 0
TotalLiabilitie 14 13 12
CommonStock 0 0 0
AdditionalPaidI 917 927 939
RetainedEarning -517 -603 -673
AccumulatedOthe 0 0 0
TotalStockholde 399 325 266
TotalLiabilitie 414 338 278
Achillion Pharmaceuticals Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Achillion Pharmaceuticals Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.